A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy

Leuk Lymphoma. 2024 Jun;65(6):843-847. doi: 10.1080/10428194.2024.2315159. Epub 2024 Feb 19.

Authors

Lindsey Murphy¹, Bradford Siegele², Billie Carstens³, Lisa Hartman⁴, Kelly Faulk⁴

Affiliations

¹ Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
² Department of Pathology and Laboratory Medicine, Children's Hospital Colorado and Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
³ Colorado Genetics Laboratory, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
⁴ Center for Cancer and Blood Disorders, Children's Hospital Colorado and Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

PMID: 38372299
DOI: 10.1080/10428194.2024.2315159

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Child
Female
Gene Rearrangement*
Histone-Lysine N-Methyltransferase* / genetics
Humans
Male
Myeloid-Lymphoid Leukemia Protein* / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Treatment Outcome

Substances

Myeloid-Lymphoid Leukemia Protein
Histone-Lysine N-Methyltransferase
KMT2A protein, human